Market rumors about Pfizer's new Guankou drug imitation license have been confirmed. On March 17, the official website of the pharmaceutical patent pool (MPP) announced that it had signed agreements with 35 companies, which were allowed to copy and produce nirmatrelvir, one of the components of paxlovid, Pfizer's new crown medicine. According to the map published on the official website, the countries involved in the agreement are distributed in 12 countries around the world, of which 6 companies will focus on the production of APIs, 9 companies will produce drugs, and the remaining 20 will have both. There are five pharmaceutical enterprises in China, including Huahai Pharmaceutical (600521), Puluo Pharmaceutical (000739), Fosun Pharmaceutical (600196), Jiuzhou Pharmaceutical (603456) and Shanghai desaino. Jiuzhou pharmaceutical only produces APIs, and others can produce APIs and preparations at the same time. It is worth noting that the agreement will help expand the accessibility of Pfizer Crown oral medicine in 95 low-income countries, which accounts for about 53% of the world's population, but does not include China. Earlier on March 17, the market spread the above news, and the above listed companies once rose the limit. Previously, it was rumored that Puluo pharmaceutical could only produce API. According to the newly released map, Puluo pharmaceutical can produce raw materials and preparations. It is noteworthy that a Ukrainian company is also on the list of 35 enterprises. MPP stated that it could not sign due to the current conflict, but it could still use the license. According to the information on the official website, the drug patent pool organization is a public health organization supported by the United Nations. It is committed to increasing access to life-saving drugs for low - and middle-income countries and promoting drug development. In January 20th, the patent pool Organization (MPP) announced its agreement with 27 pharmaceutical companies through its official website to allow the production and supply of Molnupiravir, an oral anti COVID-19 drug, to the world's 105 low and middle income countries or regions to promote the global affordability and accessibility of the drug. Fosun Pharmaceutical, Borui pharmaceutical, Shijiazhuang Longze pharmaceutical, Shanghai desaino, Langhua pharmaceutical and other five Chinese pharmaceutical enterprises ranked among them, of which the first four were licensed to produce APIs and finished drugs at the same time, and Langhua pharmaceutical was licensed to produce APIs. In other words, Fosun Pharmaceutical and Shanghai deseno pharmaceutical companies have obtained the prevention and production rights of Pfizer and MSD oral drugs. Pfizer's paxlovid is a combination of pf-07321332 and ritonavir, which has previously obtained conditional listing approval in China. Molnupiravir of mosadon is an oral form of nucleoside drug under development, which has not been approved in China. (Xinhua News Agency)